Stock Library / MCK

MCK Healthcare Latest YouTube: Q1 FY2027 Published 2026-08-06

McKesson Corporation

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

McKesson (MCK): 20% EPS Growth. A Third Of It Was Bought.

Published 2026-08-06

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked

2

Episodes linked

2

Latest video

Q1 FY2027

2026-08-06

Podcast available

Yes

Current price

$858.90

+19.90 (+2.37%)

Trailing / Forward P/E

23.04x

Forward: 16.99x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

7.7%

Earnings: -17.6%

Margins

1.3% op

Gross: 3.6% · Net: 1.1%

Balance sheet

0.89x current

Debt / Equity: —

52-week range / Beta

$673.38 - $999.00

Beta: 0.31

Analyst target

$986.94

Upside: 14.9%

Cash / shareholder return

6.79% FCF yield

Dividend yield: 0.39%

Company context

Industry: Medical Distribution

Country: United States

Employees: —

Price to book: -23.50x

Return on equity: —

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Price chart

Market context for MCK

Competitive view

MCK vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

McKesson Corporation latest YouTube video thumbnail

McKesson Corporation

MCK

YouTube Podbean

Latest video

Q1 FY2027

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Intuitive Surgical latest YouTube video thumbnail

Intuitive Surgical

ISRG

YouTube Spotify Podbean Apple

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Johnson & Johnson latest YouTube video thumbnail

Johnson & Johnson

JNJ

YouTube Podbean Apple

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

MCK

$100.14B

McKesson Corporation

ISRG

$135.72B

Intuitive Surgical

JNJ

$651.25B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

MCK

23.0x

McKesson Corporation

ISRG

43.5x

Intuitive Surgical

JNJ

31.4x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

MCK

17.0x

McKesson Corporation

ISRG

31.4x

Intuitive Surgical

JNJ

22.0x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

MCK

7.7%

McKesson Corporation

ISRG

18.5%

Intuitive Surgical

JNJ

6.6%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

MCK

-17.6%

McKesson Corporation

ISRG

26.5%

Intuitive Surgical

JNJ

-0.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

MCK

1.3%

McKesson Corporation

ISRG

33.6%

Intuitive Surgical

JNJ

29.2%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

MCK

3.6%

McKesson Corporation

ISRG

66.7%

Intuitive Surgical

JNJ

68.1%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

MCK

1.1%

McKesson Corporation

ISRG

28.4%

Intuitive Surgical

JNJ

21.5%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

MCK

—

McKesson Corporation

ISRG

17.4%

Intuitive Surgical

JNJ

25.7%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

MCK

6.8%

McKesson Corporation

ISRG

1.9%

Intuitive Surgical

JNJ

2.6%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

MCK

—

McKesson Corporation

ISRG

—

Intuitive Surgical

JNJ

57.71x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

MCK

0.89x

McKesson Corporation

ISRG

4.96x

Intuitive Surgical

JNJ

1.09x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

MCK

0.31

McKesson Corporation

ISRG

1.46

Intuitive Surgical

JNJ

0.23

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

MCK

0.4%

McKesson Corporation

ISRG

—

Intuitive Surgical

JNJ

2.0%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

MCK

14.9%

McKesson Corporation

ISRG

26.2%

Intuitive Surgical

JNJ

0.8%

Johnson & Johnson

Related research

Non-quarter videos featuring MCK

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-05

McKesson EPS +20% — But A Third Was Bought #MCK

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for MCK

Each row is one earnings episode with every verified platform link available.

Q1 FY2027

Episode live

2026-08-06

Published youtube podcast complete

McKesson (MCK): 20% EPS Growth. A Third Of It Was Bought.

Quarterly earnings-analysis entry for McKesson Corporation. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music

Q1 2026

Episode live

2026-05-09

Published youtube podcast complete

MCK Stock: Revenue Misses by 5% — Q1 2026 Earnings Analysis

Quarterly earnings-analysis entry for McKesson Corporation. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music